**Medications currently authorized for use in the United States [and] available at Children’s Hospital & Medical Center:** *Bebtelovimab*

**Mechanism of Action**: Neutralizing IgG1 monoclonal antibodies that bind to distinct epitopes within the receptor binding domain of the spike protein of SARS-CoV-2

**Indication:**

Authorized for treatment of mild to moderate COVID-19 infection in pediatric patients with positive SARS-CoV-2 viral testing (PCR or Antigen) who meet the following criteria:

* 1. ≥ 12 years
	2. ≥ 40 kg
	3. High risk\* of progressing to severe COVID-19 infections including hospitalization and/or death
	4. < 7 days from symptom onset

\*High Risk Conditions/Qualifications:

* BMI > 85th percentile for their age and gender based on CDC growth charts
* Chronic kidney disease
* Diabetes
* Immunosuppressive disease or immunosuppressive treatment
* Cardiovascular disease (including congenital heart disease) or hypertension
* Chronic lung disease (e.g., chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis, and pulmonary hypertension
* Sickle cell disease
* Neurodevelopmental disorders (e.g., cerebral palsy) or other conditions that confer medical complexity (e.g., genetic or metabolic syndromes and severe congenital anomalies)
* Use of medical-related technology (e.g., tracheostomy, gastrostomy, or positive pressure ventilation [not related to COVID-19])

*Other medical conditions or factors (e.g., race or ethnicity) may also place individual patients at high risk for progressing to severe COVID-19; authorization of COVID-19 monoclonal antibodies under the EUA is not limited to the medical conditions or factors listed above*

**Administration:**

* Single IV infusion of COVID-19 Monoclonal antibodies (duration of appointment~1.5-2 hours)
	+ 30 second IV injection time
	+ Minimum of 1 hour observation period post-infusion
* Location: Specialty Pediatric Center Infusion Center (Level 3)
* Side-Effects:
	+ Infusion-related reactions including fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, and dizziness
	+ Hypersensitivity reactions including anaphylaxis

**Exclusion**:

* Hospitalization for COVID-19, those requiring oxygen supplementation due to COVID-19, or an increase in baseline oxygen supplementation in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity

Request Form Link: <https://forms.office.com/r/KyyR1f2UyM>

Links to Health Care Provider Fact Sheets:

Bebtelovimab EUA: <https://www.fda.gov/media/156152/download>

Sotrovimab EUA: <https://www.fda.gov/media/149534/download>

Bamlanivimab-Etesevimab EUA: <https://www.fda.gov/media/145802/download>

REGEN-COV® (Casirivimab and imdevimab) EUA: <https://www.regeneron.com/downloads/treatment-covid19-eua-fact-sheet-for-hcp.pdf>

Updated 5/6/22